aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Company profile
Ticker
LIFE
Exchange
Website
CEO
Sanjay S. Shukla
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Invitrogen Corp
SEC CIK
Corporate docs
IRS number
330373077
Latest filings (excl ownership)
15-12G
Securities registration termination
14 Feb 14
15-15D
Suspension of duty to report
4 Feb 14
25-NSE
Exchange delisting
4 Feb 14
8-K
Thermo Fisher Scientific Completes Acquisition of Life Technologies Corporation
4 Feb 14
EFFECT
Notice of effectiveness
4 Feb 14
POS AM
Prospectus update (post-effective amendment)
4 Feb 14
POSASR
Automatic shelf registration (post-effective amendment)
4 Feb 14
POSASR
Automatic shelf registration (post-effective amendment)
4 Feb 14
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Feb 14
S-8 POS
Registration of securities for employees (post-effective amendment)
4 Feb 14
Latest ownership filings
SC 13G/A
Life Technologies Corp
11 Feb 15
SC 13G/A
Life Technologies Corp
14 Feb 14
SC 13G/A
Life Technologies Corp
14 Feb 14
SC 13G/A
Life Technologies Corp
14 Feb 14
SC 13G/A
Life Technologies Corp
12 Feb 14
SC 13G
Life Technologies Corp
3 Feb 14
SC 13G/A
Life Technologies Corp
29 Jan 14
SC 13D
Grace 2, Inc.
14 Nov 11
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|